Inotiv Inc (NOTV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Inotiv Inc (NOTV) has a cash flow conversion efficiency ratio of -0.014x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.07 Million) by net assets ($77.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Inotiv Inc stock valuation for the company's overall valuation and market capitalisation.
Inotiv Inc - Cash Flow Conversion Efficiency Trend (1997–2025)
This chart illustrates how Inotiv Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Inotiv Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inotiv Inc ranked by their cash flow conversion efficiency. Explore NOTV operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Onlineformapro SA
PA:MLONL
|
N/A |
|
Peel Hunt Ltd
LSE:PEEL
|
0.134x |
|
Barakah Offshore Petroleum Bhd
KLSE:7251
|
0.017x |
|
Fitness Champs Holdings Limited Common Stock
NASDAQ:FCHL
|
-1.456x |
|
Kezar Life Sciences Inc
NASDAQ:KZR
|
-0.114x |
|
Silver Spruce Resources Inc
V:SSE
|
0.000x |
|
Consolidated Firstfund Capital Corp
V:FFP
|
-0.029x |
|
Biomx Inc
NYSE MKT:PHGE
|
-0.685x |
Annual Cash Flow Conversion Efficiency for Inotiv Inc (1997–2025)
The table below shows the annual cash flow conversion efficiency of Inotiv Inc from 1997 to 2025. View Inotiv Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $136.03 Million | $-10.46 Million | -0.077x | -92.58% |
| 2024-09-30 | $170.50 Million | $-6.80 Million | -0.040x | -138.43% |
| 2023-09-30 | $268.49 Million | $27.88 Million | 0.104x | +816.16% |
| 2022-09-30 | $359.77 Million | $-5.22 Million | -0.015x | -114.19% |
| 2021-09-30 | $105.13 Million | $10.75 Million | 0.102x | -39.81% |
| 2020-09-30 | $7.60 Million | $1.29 Million | 0.170x | +2.35% |
| 2019-09-30 | $10.71 Million | $1.78 Million | 0.166x | -48.21% |
| 2018-09-30 | $10.88 Million | $3.49 Million | 0.320x | +119.47% |
| 2017-09-30 | $8.47 Million | $1.24 Million | 0.146x | +2.71% |
| 2016-09-30 | $7.46 Million | $1.06 Million | 0.142x | -25.00% |
| 2015-09-30 | $10.72 Million | $2.03 Million | 0.189x | +7.31% |
| 2014-09-30 | $9.54 Million | $1.68 Million | 0.177x | +9.97% |
| 2013-09-30 | $9.46 Million | $1.52 Million | 0.161x | +870.02% |
| 2012-09-30 | $9.59 Million | $-200.00K | -0.021x | -129.88% |
| 2011-09-30 | $15.59 Million | $1.09 Million | 0.070x | -69.50% |
| 2010-09-30 | $10.67 Million | $2.44 Million | 0.229x | +16.05% |
| 2009-09-30 | $13.12 Million | $2.59 Million | 0.197x | +486.76% |
| 2008-09-30 | $17.80 Million | $598.00K | 0.034x | -78.71% |
| 2007-09-30 | $18.55 Million | $2.93 Million | 0.158x | -28.76% |
| 2006-09-30 | $17.35 Million | $3.84 Million | 0.222x | +902.04% |
| 2005-09-30 | $19.60 Million | $-541.25K | -0.028x | -118.93% |
| 2004-09-30 | $19.42 Million | $2.83 Million | 0.146x | -2.26% |
| 2003-09-30 | $19.73 Million | $2.95 Million | 0.149x | +38.82% |
| 2002-09-30 | $18.90 Million | $2.03 Million | 0.108x | -52.39% |
| 2001-09-30 | $17.83 Million | $4.03 Million | 0.226x | +772.94% |
| 2000-09-30 | $16.06 Million | $-539.16K | -0.034x | -136.51% |
| 1999-09-30 | $17.40 Million | $1.60 Million | 0.092x | -35.63% |
| 1998-09-30 | $16.80 Million | $2.40 Million | 0.143x | +23.21% |
| 1997-09-30 | $6.90 Million | $800.00K | 0.116x | -- |
About Inotiv Inc
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences researc… Read more